Improved Outcomes With High-dose Isoniazid in Multidrug-resistant Tuberculosis Treatment in Haiti

被引：28

作者：

Walsh, Kathleen F. ^{[1
]}

Vilbrun, Stalz Charles ^{[2
]}

Souroutzidis, Ariadne ^{[3
]}

Delva, Sobieskye ^{[2
]}

Joissaint, Guy ^{[2
]}

Mathurin, Laurent ^{[2
]}

Ocheretina, Oksana ^{[1
]}

Cremieux, Pierre ^{[3
]}

Pape, Jean William ^{[2
]}

Koenig, Serena P. ^{[4
]}

机构：

[1] Weill Cornell Med, Ctr Global Hlth, New York, NY USA

[2] Haitian Grp Study Kaposis Sarcoma & Opportunist I, Port Au Prince, Haiti

[3] Harvard Med Sch, Brigham & Womens Hosp, Anal Grp, Boston, MA 02115 USA

[4] Harvard Med Sch, Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2019年 / 69卷 / 04期

基金：

美国国家卫生研究院;

关键词：

tuberculosis; high-dose isoniazid; drug resistance; MDR-TB; DRUG-RESISTANCE;

D O I：

10.1093/cid/ciz039

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We report outcomes for a cohort of patients with multidrug-resistant tuberculosis who received high-dose isoniazid in Haiti. Patients who received high-dose isoniazid had a faster time to culture conversion and higher odds of successful outcome, despite high-level isoniazid resistance. This suggests high-dose isoniazid may have effectiveness even with phenotypic resistance.

引用

页码：717 / 719

页数：3

共 10 条

[1]

[Anonymous], 2014, COMPANION HDB WHO GU

[2] Old Drugs, New Purpose: Retooling Existing Drugs for Optimized Treatment of Resistant Tuberculosis [J].

Dooley, Kelly E. ;

Mitnick, Carole D. ;

DeGroote, Mary Ann ;

Obuku, Ekwaro ;

Belitsky, Vera ;

Hamilton, Carol D. ;

Makhene, Mamodikoe ;

Shah, Sarita ;

Brust, James C. M. ;

Durakovic, Nadza ;

Nuermberger, Eric .

CLINICAL INFECTIOUS DISEASES, 2012, 55 (04) :572-581

[3] Treatment Outcomes of Isoniazid-Resistant Tuberculosis Patients, Western Cape Province, South Africa [J].

Jacobson, Karen R. ;

Theron, Danie ;

Victor, Thomas C. ;

Streicher, Elizabeth M. ;

Warren, Robin M. ;

Murray, Megan B. .

CLINICAL INFECTIOUS DISEASES, 2011, 53 (04) :369-372

[4]

Katiyar SK, 2008, INT J TUBERC LUNG D, V12, P139

[5] Meta-Analysis of Clinical Studies Supports the Pharmacokinetic Variability Hypothesis for Acquired Drug Resistance and Failure of Antituberculosis Therapy [J].

Pasipanodya, Jotam G. ;

Srivastava, Shashikant ;

Gumbo, Tawanda .

CLINICAL INFECTIOUS DISEASES, 2012, 55 (02) :169-177

[6] Rationale for high-dose isoniazid in the treatment of multidrug-resistant tuberculosis [J].

Rieder, Hans L. ;

Van Deun, Armand .

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2017, 21 (01) :123-124

[7] Tuberculosis Drug Resistance in an Area of Low Endemicity in 2004 to 2006: Semiquantitative Drug Susceptibility Testing and Genotyping [J].

Springer, Burkhard ;

Calligaris-Maibach, Romana C. ;

Ritter, Claudia ;

Boettger, Erik C. .

JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (12) :4064-4067

[8]

WHO, 2018, TECHN REP PHARM PHAR

[9]

World Health Organization, 2018, Rapid communication: key changes to treatment of multidrug-and rifampicin-resistant tuberculosis (MDR/RR-TB)

[10] Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs [J].

Zuur, Marlanka A. ;

Pasipanodya, Jotam G. ;

van Soolingen, Dick ;

van der Werf, Tjip S. ;

Gumbo, Tawanda ;

Alffenaar, Jan-Willem C. .

CLINICAL INFECTIOUS DISEASES, 2018, 67 (11) :1743-1749

← 1 →